The production and separation of 161 Tb with high specific activity at the University of Utah

Targeted radiotherapy (TRT) is an increasingly prominent area of research in nuclear medicine, particularly in the context of treating cancerous tumors. One radionuclide of considerable interest for TRT is terbium-161 (t  = 6.95 days), which undergoes beta emission and shares similar decay propertie...

Full description

Saved in:
Bibliographic Details
Published in:Applied radiation and isotopes 2024-12, Vol.214, p.111530
Main Authors: Holiski, Connor K, Bender, Aidan A, Monte, Peñafrancia F, Hennkens, Heather M, Embree, Mary F, Wang, Meng-Jen Vince, Sjoden, Glenn E, Mastren, Tara
Format: Article
Language:English
Subjects:
Nuclear Reactors
Radiopharmaceuticals - isolation & purification
Terbium - chemistry
Utah
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Targeted radiotherapy (TRT) is an increasingly prominent area of research in nuclear medicine, particularly in the context of treating cancerous tumors. One radionuclide of considerable interest for TRT is terbium-161 (t  = 6.95 days), which undergoes beta emission and shares similar decay properties as Lu (FDA-approved as LUTATHERA® and PLUVICTO®). Besides beta emission, Tb also emits a significant number of conversion and Auger electrons further enhancing its therapeutic potential. Terbium-161 can be produced using nuclear reactors through an indirect neutron capture reaction, G64160dn,γG64161d→3.66min,β T65161b, from Gd targets. However, a key challenge in utilizing Tb for TRT lies in effectively separating target and product materials to attain high specific activity for radiolabeling. Here, we detail the production of no-carrier added Tb using low flux research reactors (mean thermal (
ISSN:1872-9800